Yao L, Xuan Y, Zhang H, Yang B, Ma X, Wang T, Meng T, Sun W, Wei H, Ma X, Moses R, Xiao J, Zhang P, Ge C, Li J, Li L, Li X, Li J, Zhang B

Despite significant progression in the study of hepatocellular carcinoma (HCC), the role of the proteasome in regulating cross talk between mTOR signaling and glycolysis in liver cancer progression is not fully understood. Here, we demonstrate that deficiency of REG?, a proteasome activator, in mice significantly attenuates DEN-induced liver tumor formation. ...

Read More

Ablation of REG? increases the stability of PP2Ac (protein phosphatase 2 catalytic subunit) in vitro and in vivo, which dephosphorylates PRAS40 (AKT1 substrate 1) and stabilizes the interaction between PRAS40 and Raptor to inactive mTORC1-mediated hyper-glycolytic metabolism. In the DEN-induced animal model and clinical hepato-carcinoma samples, high levels of REG? in HCC tumor regions contribute to reduced expression of PP2Ac, leading to accumulation of phosphorylated PRAS40 and mTORC1-mediated activation of HIF1?. Interestingly, mTORC1 enhances REG? activity in HCC, forming a positive feedback regulatory loop. In conclusion, our study identifies REG?-PP2Ac-PRAS40 axis as a new layer in regulating mTORC1 activity and downstream glycolytic alterations during HCC development, highlighting the REG?-proteasome as a potential target for personalized HCC therapy.

Date: Dec. 01, 2020

View in: Pubmed Google Scholar

233325